By Denny Jacob
Regenxbio shares surged 20% after disclosing new, positive efficacy and safety data of its Duchenne muscular dystrophy treatment.
Shares were recently trading around $11.55. The stock is down 46% on the year.
The clinical-stage biotechnology company said the Phase 1/2 portion of its ongoing trial on RGX-202 found that all five participants across both dosage levels demonstrated evidence of positively impacting disease trajectory.
Regenxbio noted the trial has expanded into a multicenter, open-label pivotal Phase 1/2/3 trial of the treatment that is expected to support a biologics license application submission using the accelerated approval pathway in 2026.
"The initiation of our pivotal trial and newly released positive functional data are exciting milestones," said Chief Executive Curran Simpson.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 18, 2024 09:09 ET (14:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.